{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:12:01Z","timestamp":1793398321795,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K15693"],"award-info":[{"award-number":["22K15693"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"unrestricted research grants"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Anti-calcitonin gene-related peptide monoclonal antibodies (CGRPmAbs) have greatly changed migraine treatment options. In Japan, although CGRPmAb guidelines (\u2265\u20094 monthly migraine days (MMDs) and\u2009\u2265\u20091 previous preventive failure) are well-acknowledged, the actual use of CGRPmAbs and the circumstances of the related headache care are unknown.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted an online survey of Japanese Headache Society members, inquiring about the physicians' experience with CGRPmAbs and how they make decisions related to their use.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 397 respondents, 320 had prescribed CGRPmAbs. The threshold number of previous preventive failures for recommending a CGRPmAb was two for the majority of the respondents (<jats:italic>n<\/jats:italic>\u2009=\u2009170, 54.5%), followed by one (<jats:italic>n<\/jats:italic>\u2009=\u200964, 20.5%). The MMD threshold was\u2009\u2265\u20094 for 71 respondents (22.8%),\u2009\u2265\u20096 for 68 (21.8%),\u2009\u2265\u20098 for 76 (24.4%), and\u2009\u2265\u200910 for 81 (26.0%). The respondents tended to assess treatment efficacy after 3\u00a0months (episodic migraine: <jats:italic>n<\/jats:italic>\u2009=\u2009217, 69.6%, chronic migraine: <jats:italic>n<\/jats:italic>\u2009=\u2009188, 60.3%). The cost of CGRPmAbs was described by many respondents in two questions: (<jats:italic>i<\/jats:italic>) any request for a CGRPmAb (27.7%), and (<jats:italic>ii<\/jats:italic>) the most frequently reported reason for responders to discontinue CGRPmAbs (24.4%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Most of the respondents recommended CGRPmAbs to patients with\u2009\u2265\u20092 preventive failures, followed by\u2009\u2265\u20091. The MMD threshold ranged mostly from\u2009\u2265\u20094 to\u2009\u2265\u200910. The concern for costs was raised as a major limiting factor for prescribing CGRPmAbs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-024-01737-y","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T10:02:37Z","timestamp":1710496957000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["CGRP-monoclonal antibodies in Japan: insights from an online survey of physician members of the Japanese headache society"],"prefix":"10.1186","volume":"25","author":[{"given":"Tsubasa","family":"Takizawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Ihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narumi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Takemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Takeshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,15]]},"reference":[{"key":"1737_CR1","unstructured":"Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016 Lancet Neurol 2018;17(11):954-76."},{"issue":"1","key":"1737_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1046\/j.1468-2982.1997.1701015.x","volume":"17","author":"F Sakai","year":"1997","unstructured":"Sakai F, Igarashi H (1997) Prevalence of migraine in Japan: a nationwide survey. Cephalalgia 17(1):15\u201322","journal-title":"Cephalalgia"},{"issue":"22","key":"1737_CR3","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y, Broessner G, Bonner JH, Zhang F et al (2017) A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med 377(22):2123\u20132132","journal-title":"N Engl J Med"},{"issue":"8","key":"1737_CR4","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","volume":"38","author":"V Skljarevski","year":"2018","unstructured":"Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY (2018) Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia 38(8):1442\u20131454","journal-title":"Cephalalgia"},{"issue":"19","key":"1737_CR5","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2018) Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. JAMA 319(19):1999\u20132008","journal-title":"JAMA"},{"key":"1737_CR6","doi-asserted-by":"crossref","unstructured":"Sakai F, Ozeki A, Skljarevski V. Efficacy and safety of galcanezumab for prevention of migraine headache in Japanese patients with episodic migraine: A phase 2 randomized controlled clinical trial. Cephalalgia Reports. 2020;3.","DOI":"10.1177\/2515816320932573"},{"issue":"6","key":"1737_CR7","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/head.14138","volume":"61","author":"T Takeshima","year":"2021","unstructured":"Takeshima T, Sakai F, Hirata K, Imai N, Matsumori Y, Yoshida R et al (2021) Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study. Headache 61(6):927\u2013935","journal-title":"Headache"},{"issue":"7","key":"1737_CR8","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/head.14178","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, Suzuki N, Kim BK, Tatsuoka Y, Imai N, Ning X et al (2021) Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache 61(7):1102\u20131111","journal-title":"Headache"},{"issue":"7","key":"1737_CR9","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/head.14169","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, Suzuki N, Kim BK, Igarashi H, Hirata K, Takeshima T et al (2021) Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache 61(7):1092\u20131101","journal-title":"Headache"},{"issue":"1","key":"1737_CR10","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1186\/s12883-022-03041-1","volume":"22","author":"T Takizawa","year":"2022","unstructured":"Takizawa T, Ohtani S, Watanabe N, Miyazaki N, Ishizuchi K, Sekiguchi K et al (2022) Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis. BMC Neurol 22(1):512","journal-title":"BMC Neurol"},{"issue":"5","key":"1737_CR11","doi-asserted-by":"publisher","first-page":"333102423117764","DOI":"10.1177\/03331024231177649","volume":"43","author":"K Suzuki","year":"2023","unstructured":"Suzuki K, Suzuki S, Shiina T, Tatsumoto M, Fujita H, Haruyama Y et al (2023) Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: A 12-month, single-center, observational real-world study in Japan. Cephalalgia 43(5):3331024231177649","journal-title":"Cephalalgia"},{"issue":"1","key":"1737_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R et al (2022) European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain 23(1):67","journal-title":"J Headache Pain"},{"issue":"1","key":"1737_CR13","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s10194-023-01682-2","volume":"24","author":"JB Hong","year":"2023","unstructured":"Hong JB, Lange KS, Fitzek M, Overeem LH, Triller P, Siebert A et al (2023) Impact of a reimbursement policy change on treatment with erenumab in migraine - a real-world experience from Germany. J Headache Pain 24(1):144","journal-title":"J Headache Pain"},{"issue":"1","key":"1737_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/head.13456","volume":"59","author":"HS American","year":"2019","unstructured":"American HS (2019) The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. Headache 59(1):1\u201318","journal-title":"Headache"},{"key":"1737_CR15","unstructured":"GoodRx. http:\/\/www.goodrx.com Accessed Oct. 13, 2023."},{"issue":"5","key":"1737_CR16","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s40122-023-00538-6","volume":"12","author":"J Pascual","year":"2023","unstructured":"Pascual J, Nunez M, Panni T, Diaz-Cerezo S, Novick D, Ciudad A (2023) Burden and Unmet Needs in Migraine Patients: Results from the OVERCOME (Spain) Study. Pain Ther 12(5):1209\u20131220","journal-title":"Pain Ther"},{"key":"1737_CR17","unstructured":"National Health Insurance Administration. Ministry of Health and Welfare, Taiwan. National Health Insurance in Taiwan. https:\/\/eng.nhi.gov.tw\/en\/mp-2.html. Accessed 13 Oct 2023."},{"issue":"1","key":"1737_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s10194-023-01556-7","volume":"24","author":"K Ihara","year":"2023","unstructured":"Ihara K, Ohtani S, Watanabe N, Takahashi N, Miyazaki N, Ishizuchi K et al (2023) Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study. J Headache Pain 24(1):23","journal-title":"J Headache Pain"},{"issue":"11","key":"1737_CR19","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1212\/WNL.0000000000207292","volume":"101","author":"P Barbanti","year":"2023","unstructured":"Barbanti P, Aurilia C, Egeo G, Torelli P, Proietti S, Cevoli S et al (2023) Late Response to Anti-CGRP Monoclonal Antibodies in Migraine: A Multicenter Prospective Observational Study. Neurology 101(11):482\u2013488","journal-title":"Neurology"},{"key":"1737_CR20","unstructured":"National Tax Agency. Statistical Survey of Actual Status for Salary in the Private Sector. https:\/\/www.nta.go.jp\/publication\/statistics\/kokuzeicho\/minkan\/gaiyou\/2022.htm. (in Japanese) Accessed on Dec. 23, 2023."},{"issue":"1","key":"1737_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s10194-021-01252-4","volume":"22","author":"S Sacco","year":"2021","unstructured":"Sacco S, Lampl C, Maassen van den Brink A, Caponnetto V, Braschinsky M, Ducros A et al (2021) Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance. J Headache Pain 22(1):39","journal-title":"J Headache Pain"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01737-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-024-01737-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01737-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T10:02:45Z","timestamp":1710496965000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-024-01737-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1737"],"URL":"https:\/\/doi.org\/10.1186\/s10194-024-01737-y","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,15]]},"assertion":[{"value":"25 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Keio University School of Medicine (approval no. 20221100). Participants were informed about the purpose and the content of the study through the online survey form. The need for informed consent was waived by the Ethics Committee of the Keio University School of Medicine in accordance with national regulations (Ethical Guidelines for Medical and Biological Research Involving Human Subjects).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TsT is a consultant\/advisor and\/or serves on an advisory board for Eli Lilly, Otsuka, Amgen, Pfizer, and Teijin and has received speaker honoraria from Eli Lilly, Daiichi Sankyo, Otsuka, Amgen, Kowa, Kyowa Kirin, Eisai, UCB Japan, Takeda, and Santen Pharmaceutical and grant\/funding from Eli Lilly, Pfizer and Tsumura outside the submitted work. MS has received lecture fees from Eli Lilly Japan, Daiichi Sankyo, Amgen, and Otsuka Pharmaceutical Co., Ltd. KS\u00a0has received lecture fees from Eli Lilly Japan, Daiichi Sankyo, Amgen, and Otsuka Pharmaceutical Co., Ltd. NI reports being an advisor for Sawai and has received speaker fees from Daiichi Sankyo, Eli Lilly, Otsuka, and Amgen. NS has received speaker honoraria from Otsuka and Daiichi Sankyo. KH is a consultant\/advisor for Otsuka and Sawai and has received speaker honoraria from Eli Lilly, Daiichi Sankyo, Otsuka, and Amgen. TaT is a consultant\/advisor for Hedgehog MedTech and Sawai and has received speaker honoraria from Eli Lilly, Daiichi Sankyo, Otsuka, and Amgen. JN has received honoraria and research scholarships from Amgen and Daiichi Sankyo.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}